New Bird Flu Vaccine Shows Promise Against Multiple H5N1 Strains

Key Takeaways

• Vaccine protects mice and calves from multiple H5N1 strains
• Intramuscular + intranasal delivery induces systemic and mucosal immunity
• No licensed H5N1 vaccine exists for cattle currently
• Platform could enable multispecies vaccine, including humans
• Outbreak has caused >166 million US poultry deaths since 2022

Pulse Analysis

Since 2022, highly pathogenic H5N1 avian influenza has devastated U.S. poultry, prompting the culling of more than 166 million birds and generating billions of dollars in loss. In early 2024 the virus jumped to dairy cattle, sparking infections across the Midwest and causing illness in roughly 70 farm workers with direct exposure. This interspecies spillover raised alarms about viral adaptation, as each new host offers mutation opportunities that could enhance human transmissibility. The outbreak highlighted the urgent need for a vaccine that protects livestock and curtails pandemic risk.

University of Nebraska–Lincoln scientists created a nanodisc‑based platform that displays conserved H5 hemagglutinin epitopes on a lipid‑wrapped particle, mimicking the virus’s structure and triggering both humoral and mucosal immunity. Dairy calves were primed at one week old via intramuscular injection and received an intranasal booster four weeks later; mice followed a similar schedule. This dual delivery generates systemic antibodies to block viremia and mucosal defenses to prevent respiratory shedding. Vaccinated animals produced high neutralizing titers and survived lethal challenges from several divergent H5N1 clades without clinical signs.

The breakthrough matters because no licensed H5N1 vaccine exists for cattle, leaving producers exposed to herd losses and depressed milk prices. By stopping viral replication in livestock, the platform safeguards agricultural revenue and reduces the reservoir for zoonotic spillover, delivering economic and public‑health benefits. Weaver’s team is seeking biotech partners and federal grants to fund manufacturing, field trials, and a multispecies formulation that could protect poultry, cattle, and high‑risk humans such as farm workers. Success could make the technology a cornerstone of global influenza preparedness and a model for rapid vaccine development against emerging avian strains.